Crossover hits overall survival, pouring doubts on the group’s deal hopes.

Jaypirca secures a CLL label, though plans to dominate will be tempered by this market’s fast-changing nature.

AstraZeneca and Lilly put PARP1 and KRAS G12C inhibitors into their first phase 3s, while Amgen advances DLL3 into early-stage disease.

The study of Novartis’s Pluvicto in pre-chemo prostate cancer is a bust on overall survival, with questions raised about trial design.

Astra manages to avoid the toxicities that scuppered Lilly’s PD-1 x TIM-3 contender, but still needs to dial up sabestomig’s efficacy.

Leaked data ahead of the ESMO late breaker show a progression-free survival benefit that looks practice-changing.

But Repare and Black Diamond still have rebuilding to do.